8-K/A: Harvard Bioscience Amends 8-K to Detail Nasdaq Audit Committee Non-Compliance

Harvard Bioscience, Inc. has filed an amended Form 8-K to disclose its non-compliance with Nasdaq's audit committee composition requirements following a director's resignation, and outlines its plan to regain compliance.

Summary

• Harvard Bioscience, Inc. (HBIO) filed an Amendment No. 1 to its Current Report on Form 8-K to update information regarding its compliance with Nasdaq listing rules.
• The Company is currently not in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which specifies the required composition of the audit committee.
• This non-compliance is a direct result of a vacancy on the Audit Committee, following the resignation of Alan Edrick from both the Board and the Audit Committee, effective June 10, 2025.
• On June 18, 2025, Harvard Bioscience formally notified the Nasdaq Stock Market LLC of its non-compliance.
• Subsequently, on June 26, 2025, the Company received a letter from Nasdaq's Listing Qualifications Department staff, officially confirming its determination of non-compliance with the Audit Committee Composition Requirement.
• The Company intends to regain compliance by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as expeditiously as practicable.
• Harvard Bioscience plans to utilize the cure period provided by Nasdaq Listing Rule 5605(c)(4), which grants the Company until the earlier of its next annual meeting of stockholders or June 10, 2026, to satisfy the Audit Committee Composition Requirement.

Sentiment

Score: 4

Explanation: The document indicates a negative event (non-compliance with Nasdaq listing rules) due to a director's resignation. While the company has a plan to regain compliance and a cure period, the initial non-compliance is a governance setback.

Positives

• The Company has a clear stated intention and plan to regain compliance by appointing a new independent Board member.
• Harvard Bioscience is utilizing the Nasdaq cure period, which provides a defined timeframe to resolve the non-compliance issue without immediate delisting.

Negatives

• Harvard Bioscience is currently non-compliant with Nasdaq's Audit Committee Composition Requirement (Rule 5605(c)(2)(A)).
• The non-compliance was triggered by the resignation of a key Board and Audit Committee member, Alan Edrick, creating a vacancy.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) within the specified cure period (by the earlier of the next annual meeting of stockholders or June 10, 2026) could lead to the delisting of the Company's common stock from the Nasdaq Stock Market.
• Potential reputational damage and decreased investor confidence due to non-compliance with corporate governance standards.

Future Outlook

Harvard Bioscience intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by expeditiously appointing a new Board member who meets the independence requirements. The Company plans to rely on the cure period, which extends until the earlier of its next annual meeting of stockholders or June 10, 2026.

Management Comments

• "The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable."
• "Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company’s next annual meeting of stockholders or (ii) one year from Mr. Edrick’s resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement."

Industry Context

Compliance with exchange listing rules, particularly those related to corporate governance and audit committee independence, is a fundamental requirement for publicly traded companies. An independent and properly constituted audit committee is crucial for financial oversight, risk management, and maintaining investor confidence. Non-compliance, even if temporary, can raise concerns about internal controls and governance practices, potentially impacting investor perception and stock valuation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact on investor confidence and share price due to corporate governance non-compliance and the risk of delisting if not resolved.
• Board of Directors: Increased pressure to identify and appoint a suitable independent director expeditiously to fill the vacancy.
• Nasdaq: Requires monitoring and enforcement of listing rules to ensure compliance.

Next Steps

• Appoint a new Board member who meets Nasdaq's independence requirements.
• Regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) within the cure period (by the earlier of the next annual meeting of stockholders or June 10, 2026).

Key Dates

Keywords

Harvard Bioscience, HBIO, SEC filing, Form 8-K/A, Nasdaq, listing rules, audit committee, corporate governance, compliance, director resignation, financial reporting, risk management